Press Enter to search · ESC to close

US Stocks

Akeso Shares Plunge Over 24% After FDA Rejection of Ivonescimab

Akeso’s shares fell more than 24% after the US Food and Drug Administration declined to approve the company’s first marketing application for ivonescimab, its oncology immunotherapy drug, in the United States. The drop followed the rejection of the China-based biotech’s bid to launch the drug in the US market.

Share

Related News

Cointime share card
Long-press the image to save or share
Pitch us Community Feedback